Patients with lung adenocarcinoma who have driver mutations, such as EGFR mutations, ALK fusions, etc., then targeted drugs that target this mutation can be used with high efficiency and less adverse effects. If there are no mutations, the efficiency of treatment with these targeted drugs is low, and chemotherapy and immunotherapy are the mainstay of treatment for patients with advanced disease.
Patients with lung adenocarcinoma who have driver mutations, such as EGFR mutations or ALK fusions, can be treated with targeted agents that target this mutation with high efficiency and fewer adverse effects. If there is no mutation, the efficiency of treatment with these targeted drugs is low, and chemotherapy and immunotherapy are the main treatments for patients with advanced stage. Lung cancer is a common malignant tumor of the respiratory system. The exact cause of the disease is not very clear, but it is related to smoking, air pollution and occupational environment, etc. Typical symptoms are coughing, coughing and blood in sputum. After diagnosis, surgery is preferred to reduce the tumor load, postoperative chemotherapy is given to control microscopic lesions, combined with radiotherapy to control local tumor cells and reduce the rate of recurrence and metastasis. 5-year survival rate of stage IA is 70%-80%, 5-year survival rate of stage IB is 50%-60%, and 5-year survival rate of stage II is 40%-55%. Early stage cancer is better treated and has a higher cure rate. People who smoke for a long time, especially those who smoke 20 cigarettes a day and have smoked for more than 20 years, those who work in occupations related to toxic substances, such as those working with toxic gases such as asbestos, arsenic, chrome, nickel, etc., those with a family history of lung cancer, those with low immune function, and those who use immunosuppressants for a long time, need to have regular screening for related tumors.